UNCY News and Press, Unicycive Therapeutics Inc. From 03/07/23

2023-03-07 11:28:43 ET Gainers: Unicycive ( UNCY ) +52% . Bionomics ( BNOX ) +49% . Novo Integrated Sciences ( NVOS ) +37% . Protagonist Therapeutics ( PTGX ) +34% . Allakos ( ALLK ) +22% . Losers: Cara ( CARA ) -28...

(NewsDirect) By Julian Richard, Benzinga Unicycive Therapeutics Inc (NASDAQ: UNCY) is a biopharmaceutical company spearheading efforts to develop effective, safe, and novel treatments for kidney disease to improve patient and caregiver quality of life due to kidney failure. Its candid...

2023-03-07 06:00:00 ET 3 Penny Stocks Trading Tips for When the Market is Volatile When it comes to trading penny stocks, market uncertainty can be a challenge. But with the right strategies in place, traders can navigate volatile markets and make profitable trades. In this article, we&...

2023-03-06 07:54:24 ET Shares of kidney disease company, Unicycive Therapeutics ( NASDAQ: UNCY ) jump 114% premarket after the Company signed a securities purchase agreement with certain institutional investors that will provide up to $130M in gross proceeds to Unicyci...

$30 million financing upfront with up to an additional $100 million tied to satisfaction of milestones Led by Vivo Capital with participation from RA Capital, BVF Partners, Logos Capital, and supported by existing investors Nantahala Capital Partners and Rosalind Advisors Inc. Viv...

(NewsDirect) By Julian Richard, Benzinga Unicycive Therapeutics Inc (NASDAQ: UNCY) is a biopharmaceutical company committed to developing effective and safe treatments for kidney (renal) disease to reduce death rates and improve patients and their caregivers' quality of life by combin...

Data from two abstracts supporting UNI-494’s potential to treat acute and chronic kidney injury accepted for presentation at the 28 th International Conference on Critical Care in Nephrology: the Acute Kidney Injury & CRRT 2023 Conference Highlights key role mitocho...

--News Direct-- Doug Jermasek, Executive Vice President, Corporate Strategy for Unicycive Therapeutics, Inc. (NASDAQ: UNCY), was recently interviewed by Benzinga. Unicycive is a biotechnology company focused on solutions for important and underserved renal diseases. The company curren...

(NewsDirect) By Johnny Rice, Benzinga Unicycive Therapeutics Inc. (NASDAQ: UNCY) is a biotechnology company developing drug candidates currently focused on kidney disease. The innovative treatments may have vast potential outside of the specifics of kidney disease as well. Current...

Unicycive Therapeutics ( NASDAQ: UNCY ) signed a license agreement with Lotus Pharmaceutical to develop and commercialize Renazorb in the Republic of Korea. Renazorb (lanthanum dioxycarbonate) is a novel phosphate binding agent being developed by Unicycive to treat hyperphos...